August 24, 2011 – RaySearch Laboratories has received an order for its RayStation treatment planning system from Health Quest Systems Inc., headquartered in LaGrange, N.Y.
Health Quest’s radiation oncology enterprise comprises the departments of four community locations that have been serving regional patients in New York’s Mid-Hudson Valley since 1887: Dyson Cancer Center at Vassar Brothers Medical Center in Poughkeepsie; Ulster Radiation Oncology Center in Kingston, a joint venture with Benedictine Hospital; Fishkill Radiation Oncology in Fishkill; and Wagner Cancer Pavilion at Putnam Hospital Center in Carmel.
Health Quest will use RayStation as its treatment planning system for advanced treatments, such as intensity-modulated radiotherapy (IMRT), and will be serving the four treatment centers with a central patient database and thin client access throughout the departments. Health Quest will systematically replace its current treatment planning system with RayStation for all external beam treatment planning over a phased transition period.
The order also includes multi-criteria optimization, which is an advanced product enabling a more efficient treatment planning process. This highly intuitive tool lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming treatment planning optimization process.
Health Quest Systems Senior Medical Physicist George Sherouse said, “I have been privileged in my career to be present at the launch of several game-changing innovations in radiation oncology treatment planning. As the first totally new commercial platform in some time, designed and built by an established industry leading software house, RayStation promises to be another game-changer. The rate at which RaySearch is able to deliver innovations in clinical software is remarkable to me. I’m thrilled to have the opportunity to lead an early adopter team at Health Quest.”
For more information: www.raysearchlabs.com
April 21, 2025 
